https://www.biopharmawatch.com/news/RGNX/regenxbio-regulatory-update-rgx-121-mps-ii BiopharmaWatch en 2026-08-24T11:05:00.000Z REGENXBIO Announces Regulatory Update on RGX-121 for MPS II https://www.biopharmawatch.com/news/ACB/aurora-cannabis-curaleaf-hostile-bid-response BiopharmaWatch en 2026-08-24T11:05:00.000Z AURORA CANNABIS CORRECTS INACCURATE STATEMENTS MADE IN SUPPORT OF CURALEAF HOLDINGS' HOSTILE BID https://www.biopharmawatch.com/news/LH/labcorp-fda-cleared-blood-test-alzheimers-disease BiopharmaWatch en 2026-08-24T11:02:00.000Z Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings https://www.biopharmawatch.com/news/GH/twinstrand-biosciences-guardant-health-patent-infringement BiopharmaWatch en 2026-08-24T11:00:00.000Z TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-appoints-cameron-trenor-cmo BiopharmaWatch en 2026-08-24T11:00:00.000Z AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/UTHR/fda-acceptance-ralinepag-pah-uthr BiopharmaWatch en 2026-08-24T11:00:00.000Z United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension https://www.biopharmawatch.com/news/SCNI/scinai-first-half-2026-highlights-results BiopharmaWatch en 2026-08-24T11:00:00.000Z Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum https://www.biopharmawatch.com/news/INSM/brinsupr-approved-japan-non-cystic-fibrosis-bronchiectasis BiopharmaWatch en 2026-08-24T11:00:00.000Z BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease https://www.biopharmawatch.com/news/PLSM/pulsenmore-announces-financial-results-2026 BiopharmaWatch en 2026-08-24T11:00:00.000Z Pulsenmore Ltd. To Announce Financial Results and Business Highlights and Hold Conference Call for the First Half of 2026 https://www.biopharmawatch.com/news/VNDA/vanda-orphan-designation-imsidolimab-gpp-eu BiopharmaWatch en 2026-08-24T11:00:00.000Z Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission https://www.biopharmawatch.com/news/VRXA/veraxa-secarna-research-milestone-antibody-oligonucleotide BiopharmaWatch en 2026-08-24T11:00:00.000Z VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance https://www.biopharmawatch.com/news/TLSA/tiziana-life-sciences-banyan-trial-als-nexus-2026 BiopharmaWatch en 2026-08-24T11:00:00.000Z Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 https://www.biopharmawatch.com/news/INCR/intercure-settlement-war-damages-nir-oz-facility BiopharmaWatch en 2026-08-24T11:00:00.000Z InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages https://www.biopharmawatch.com/news/BMEA/biomea-fusion-completes-enrollment-covalent-211-trial BiopharmaWatch en 2026-08-24T11:00:00.000Z Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-kol-event-bipolar-mania-rap-219 BiopharmaWatch en 2026-08-24T11:00:00.000Z Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-modefire-1-phase-2-study BiopharmaWatch en 2026-08-24T11:00:00.000Z Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-appoints-henry-gosebruch-board BiopharmaWatch en 2026-08-24T10:55:00.000Z ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors https://www.biopharmawatch.com/news/GILD/gilead-trodelvy-expands-role-tnbc BiopharmaWatch en 2026-08-24T10:31:00.000Z European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status https://www.biopharmawatch.com/news/DTIL/precision-biosciences-dosing-phase-1-2-function-dmd-study BiopharmaWatch en 2026-08-24T10:01:00.000Z Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study https://www.biopharmawatch.com/news/OCS/first-patient-treated-pioneer-1-trial-privosegtor-optic-neuritis BiopharmaWatch en 2026-08-24T08:00:00.000Z First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-08-24 BiopharmaWatch en 2026-08-24T07:15:32.636Z Biotech Catalysts to Watch: Key Developments for Q4 2026 https://www.biopharmawatch.com/news/ACAD/european-commission-approves-daybu-trofinetide-rett-syndrome BiopharmaWatch en 2026-08-24T07:01:00.000Z European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union https://www.biopharmawatch.com/news/ACAD/daybu-approval-rett-syndrome-eu BiopharmaWatch en 2026-08-24T07:01:00.000Z De Europese Commissie keurt DAYBU® (trofinetide) goed als eerste en enige behandeling voor neurologische gedragssymptomen van het Rett-syndroom in de Europese Unie https://www.biopharmawatch.com/news/TAK/orzeiful-oveporexton-approval-japan-narcolepsy BiopharmaWatch en 2026-08-24T06:36:00.000Z ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 https://www.biopharmawatch.com/news/VNDA/nereus-sponsor-no-47-indycar-freedom-250-grand-prix BiopharmaWatch en 2026-08-22T19:16:00.000Z NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.